Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600129104) titled 'Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) in Kidney Transplant Recipients with Chronic Active Antibody-Mediated Rejection' on July 31.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: West China Hospital of Sichuan University
Condition:
Kidney Transplant Recipients with Chronic Active Antibody-Mediated Rejection (cAMR)
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-07-31
Target Sample Size: Bispecific T cell engager treatment group:50;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?...